Evidence map›Paper›PMID 42905163›Full record

ArticleJournal of molecular modeling2026

Contrasting binding architectures underlying the asymmetric M327I resistance of menin inhibitors.

Yiquan Wang, Kai Wei

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yiquan WangXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China. ethan@stu.xju.edu.cn.ORCID https://orcid.org/0000-0003-1417-5752
Kai WeiXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China. kaiwei@xju.edu.cn.ORCID https://orcid.org/0000-0001-5431-8290

Funding

Key Research and Development Project of Xinjiang Autonomous Region, China 2025B02008-1Natural Science Foundation of Xinjiang Uygur Autonomous Region 2024D01C216
6 · The paper itself

Abstract

contextThe interaction between menin and mixed lineage leukemia fusion proteins represents a critical therapeutic target. The clinical inhibitors revumenib and ziftomenib display divergent resistance profiles against the M327I mutation, which frequently compromises revumenib efficacy while ziftomenib maintains potency. Molecular dynamics simulations of a complete

methodsTwelve independent 500 ns molecular dynamics simulations (four systems

Indexed as

Drug Resistance, NeoplasmMolecular Dynamics SimulationProto-Oncogene ProteinsBinding SitesHumansHydrogen BondingMutationProtein BindingMEN1 protein, humanProto-Oncogene ProteinsBinding architecture asymmetryDrug resistance mechanismMenin-KMT2A inhibitorMM/GBSA energy decompositionMolecular dynamics simulation

Identifiers

PMID42905163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.